Still not depressed from my assesment atleast ; how do you explain this generalised anxiety, could this be a sequele of previous psychotic illness olanzapine a i just hoping she will do well without an antipsychotic because otherwise it will be a bit too soon for her and all of us close to her to go through the same period again.

Cohort compared to either the olanzapine or risperidone cohort. For example, as Figure 1 illustrates, patients treated with quetiapine had a 4.37% reduction in the rate of hospitalization when comparing the 6 months before initiation to the 6 months after, while patients initiated with olanzapine or risperidone had significant increases in hospitalization rates 2.19% and 1.72%, respectively ; . The figures also show how changes in hospitalizations and ED use from the 6 months prior to the 6 months post initiation on medication differs for patients who have been diagnosed with either schizophrenia or bipolar disorder. The results for patients diagnosed with bipolar disorder are similar to the findings for all patients. Namely, compared to patients who initiated therapy with either olanzapine or risperidone, patients who initiated therapy with quetiapine had significantly less hospitalizations and ED visits as well as a. Zyprexa, effects side zyprexa, lawsuit zyprexa, diabetes zyprexa, zydis zyprexa, withdrawal zyprexa, settlement zyprexa, attorney francisco san zyprexa, medication zyprexa, lawyer zyprexa, lawyer pennsylvania zyprexa, news zyprexa, attorney zyprexa, information zyprexa, gain weight zyprexa, litigation zyprexa, attorney connecticut zyprexa, generic zyprexa, drug zyprexa, action class zyprexa, olanzapine zyprexa, florida lawyer zyprexa, effect side zyprexa, overdose zyprexa, cheap zyprexa, lawyer new york zyprexa, georgia lawyer zyprexa, lawyer texas zyprexa, chicago lawyer zyprexa, attorney florida zyprexa, eli lawsuit lilly zyprexa, death zyprexa, atlanta lawyer zyprexa, california lawyer zyprexa, illinois lawyer zyprexa, tablet zyprexa, hyperglycemia zyprexa, atlanta attorney zyprexa, connecticut lawyer zyprexa, lawyer ohio zyprexa, attorney georgia zyprexa, action class lawsuit zyprexa, depression zyprexa, alternative zyprexa, diabetes effects side zyprexa, diabetes risk zyprexa, dosage zyprexa, hartford lawyer zyprexa, attorney hartford zyprexa, attorney orlando zyprexa, lawyer massachusetts zyprexa, law suit zyprexa, n zyprexa, diabetes lawsuit zyprexa, lawyer louisiana zyprexa, anxiety zyprexa, attorney texas zyprexa, attorney washington zyprexa, lawyer settlement zyprexa, alcohol zyprexa, common effects side zyprexa, eli lilly settlement zyprexa, eli lawyer lilly zyprexa, lawyer virginia zyprexa, attorney pennsylvania zyprexa, effects zyprexa, news settlement zyprexa, recall zyprexa, schizophrenia zyprexa, firm law zyprexa, forum zyprexa, attorney massachusetts zyprexa, attorney ohio zyprexa, prozac zyprexa, child zyprexa, effects olanzapine side zyprexa, bipolar zyprexa, depression manic zyprexa, pregnancy zyprexa, daniel haszard zyprexa, houston lawyer zyprexa, ocd zyprexa, add zyprexa, attorney colorado zyprexa, bipolar disorder zyprexa, action class law suit zyprexa, action class suit zyprexa, child diabetes from zyprexa, insomnia zyprexa. A typical example of such a solvate salt is the acetone solvate of olanzapine succinate. B. Patient preparation 1. Patients should have a proven, inoperable neuroendocrine tumour and have undergone conventional staging investigations including mIBG scintigraphy, anatomical imaging CT or MRI ; and biochemical assessment to identify objective tumour markers. 2. Eligible patients will have mIBG-positive tumours, documented by quantitative tracer scintigraphy. It is essential that all known tumour sites are mIBG positive. 3. Drugs likely to interfere with the uptake and or retention of 131I-mIBG should be withdrawn for 12 weeks prior to treatment. Patients should be stabilised on alternative medication prior to therapy. Patients with metabolically active catecholamine-secreting tumours phaeochromoctyoma, paraganglioma ; should be alpha and beta blocked prior to treatment. 157164. 4. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002; 32: 4759. Herholz K. PET studies in dementia. Ann Nucl Med 2003; 17: 7989. Cohen RM, Semple WE, Gross M, Nordahl TE, King AC, Pickar D, et al. Evidence for common alterations in cerebral glucose metabolism in major affective disorders and schizophrenia. Neuropsychopharmacology 1989; 2: 241254. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Ther 2000; 293: 814. Laurie DJ, Pratt JA. Local cerebral glucose utilization following subacute and chronic diazepam pretreatment: differential tolerance. Brain Res 1989; 504: 101111. Grasby PM, Sharp T, Allen T, Kelly PA, Grahame-Smith DG. Effects of the 5-HT1A partial agonists gepirone, ipsapirone and buspirone on local cerebral glucose utilization in the conscious rat. Psychopharmacology Berl ; 1992; 106: 97101. Potkin SG, Buchsbaum MS, Jin Y, Tang C, Telford J, Friedman G, et al. Clozapine effects on glucose metabolic rate in striatum and frontal cortex. J Clin Psychiatry 1994; 55: 6366. Moresco RM, Tettamanti M, Gobbo C, Del Sole A, Ravasi L, Messa C, et al. Acute effect of 3- 4-acetamido ; -butyrrillorazepam DDS2700 ; on brain function assessed by PET at rest and during attentive tasks. Nucl Med Commun 2001; 22: 399404. Frykholm P, Andersson JL, Valtysson J, Silander HC, Hillered L, Perss Olsson Y, et al. A metabolic threshold of irreversible ischemia demonstrated by PET in a middle cerebral artery occlusion-reperfusion primate model. Acta Neurol Scand 2000; 102: 1826. Le Mestric C, Chavoixs C, Chapon F, Mezenge F, Epelbaum J, Baron JC. Effects of damage to the basal forebrain on brain glucose utilization--a reevaluation using positron emission tomography in baboons with extensive unilateral excitotoxic lesion. J Cereb Blood Flow Metab 1998; 18: 476490. Kobayashi K, Inoue O, Watanabe Y, Onoe H, Langltrom B. Difference in response of D2 receptor binding between 11CN-methylspiperone and 11C-raclopride against anesthetics in rhesus monkey brain. J Neural Transm Gen Sect 1995; 100: 147151. Otsuka T, Wei L, Bereczki D, Acuff V, Patlak C, Fenstermacher J. Pentobarbital produces dissimilar changes in glucose influx and utilization in brain. J Physiol 1991; 261: 265275. Momosaki S, Hatano K, Kawasumi Y, Kato T, Hosoi R, Kobayashi K, et al. Rat-PET study without anesthesia: anesthetics modify the dopamine D1 receptor binding in rat brain. Synapse 2004; 54: 207213. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 1999; 843: 171183 and omeprazole.
Leave it to a qualified medical doctor to determine how and why. 4. When rapid-cycling patients were treated with a mood stabilizer plus quetiapine for 6 months: a. Mania and depression rating scores improved b. Sedation was the most common side effect c. Patients' weight did not change markedly d. 27 of the 41 patients withdrew for lack of efficacy, side effects, or other reasons e. All of the above 5. Studies with which agent first suggested a role for atypical antipsychotics in treatment-refractory mania? a. Risperidone b. Olanzapine c. Clozapine d. Quetiapine e. Ziprasidone 7. For bipolar patients with primarily manic episodes, which agent may be the preferred therapy? a. Clozapine b. Lamotrigine c. Haloperidol d. Lithium e. Gabapentin and ondansetron.

The diagnosis, treatment and management of coronary artery disease CAD ; , the leading cause of death in Canadians, has evolved remarkably in the past 25 years. Hundreds of thousands of lives have been saved and post-infarction quality of life has improved dramatically. A concentrated effort is now being made to better understand the processes and influencers of what are now referred to as "Acute Coronary Syndromes" ACS ; , with a goal to further improving potential outcomes for patients. ACS are characterized by disproportion between myocardial oxygen supply and demand. ACS include the following conditions: Unstable angina UA ; . Non-ST-segment elevation myocardial infarction NSTEMI ; , previously known as non-Q-wave MI. ST-segment elevation myocardial infarction STEMI ; , previously Q-wave MI. STEMI is characterized by complete occlusion of a coronary artery, and is usually treated with immediate reperfusion therapy. Experts group UA and NSTEMI together as NSTE-ACS non-ST-segment acute coronary syndromes ; . In contrast to STEMI, NSTE-ACS are characterized by a reduction in myocardial perfusion, usually caused by a non-occlusive thrombus formed in a narrowing in a coronary artery often disrupted plaque ; . If the ischemia is severe enough, myocardial damage can occur that is detectable by laboratory markers of myocardial injury. Revascularization may or may not be necessary. The most recent update to the American College of Cardiology American Heart Association guidelines for NSTEMI Circulation 2002; 106: 18931900 ; recommends four assessment steps that are helpful in this process: 1. History--with a focus on anginal symptoms and possible noncoronary causes that could explain development of symptoms. 2. Physical examination--major objectives are to assess the hemodynamic impact of the possible ischemic event e.g. pulmonary edema, hypotension, rhythm disturbances, S3 gallop, new murmur ; , identify precipitating causes e.g. uncontrolled hypertension or thyrotoxicosis ; and determine presence of any other cardiac disease or comorbid conditions e.g. pulmonary disease ; . 3. 12-lead electrocardiogram ECG ; -- should be obtained immediately in patients with ongoing chest discomfort. Transient ST-segment changes that develop during symptomatic episodes at rest and resolve when patient is asymptomatic strongly suggest acute ischemia and underlying severe CAD. 4. Biomarkers of cardiac injury--the preferred marker is cardiac-specific troponins, as they can detect lesser degrees of myocardial damage thought to represent microinfarctions resulting from microemboli from an unstable plaque ; . Creatinine phosphokinase-MB isoenzyme CK-MB ; is acceptable. If negative when performed within six hours of pain onset, the test should be repeated between 612 hours after onset of pain. Both cardiac troponins and CK-MB have limited sensitivity in very early phase of MI. ; See informed plus #11220 for more information. NSTE-ACS should be considered in patients presenting with clinical evidence of myocardial ischemia, but without evidence of: ST-segment elevation. A true posterior MI. New left bundle-branch block. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, Tang W, Wiener K, Dvorin S, Dietz MB. Prevalence of the metabolic syndrome among patients receiving clozapine. J Psychiatry. 2006 Jul; 163 7 ; : 1273-6. Lee PE, Sykora K, Gill SS, Mamdani M et al. Antipsychotic medications & drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Geriatr Soc. 2005 Aug; 53 8 ; : 1374-9. Leopold NA. Risperidone Treatment of Drug Related Psychosis in Patients with Parkinsomism. Movement Disorders 2000; 15 1 ; : 301-304. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. J Psychiatry. 2004 Sep; 161 9 ; : 1709-11. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003 May 10; 361 9369 ; : 1581-9. Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness CATIE ; Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22; 353 12 ; : 1209-23. Epub 2005 Sep 19. & see also Pharmacist Letter Nov 05. CONCLUSIONS: The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons. Olanzapine was the most effective in terms and zofran.
Pharmacotherapy Antipsychotic drugs introduced in the early 1950s revolutionized schizophrenia treatment. At present, there are two major classes of antipsychotic drugs available, variously referred to as: 1 ; traditional, typical, or conventional antipsychotic agents e.g., phenothiazines, butyrophenones, thioxanthenes, dihydroindolones, and dibenzoxazepines ; , which can broadly be classified as dopaminergic antagonists, and 2 ; the newer atypical antipsychotic agents i.e., clozapine, olanzapine, risperidone, quetiapine, and ziprasidone ; . Antipsychotic drugs produce a wide variety of physiological actions, only some of which are essential to their therapeutic action. The limitations of the traditional antipsychotic agents are well documented and include a higher incidence of EPS at therapeutic doses due to antagonism of dopaminergic Psychoses. How do consumers discover that their complaint about a pharmacist or pharmacy needs to be directed to the North Carolina Board of Pharmacy? One reason this question arose is the developing world of technology. The North Carolina Board of Pharmacy maintains a Web site that contains useful information on a broad range of topics. One of these subjects includes the filing of complaints related to pharmacy practice with the Board. Although this Internet access to information about making complaints has been available for quite some time, there has not been any data collected on how many people actually utilize this route when making a complaint. In order to obtain this data, a follow-up survey was developed to use for calling recent complainants. A list was obtained from the Board's database for complaints made during 2004 and 2005. Meredith Smith, a PharmD candidate from the University of North Carolina, utilized this list to contact people and complete surveys in May 2005. She placed calls and completed the survey based on answers provided by consumers. A and oxcarbazepine. 227716 28 July, 2003 Class 5. Pharmaceutical preparations and substances; vitamin and mineral preparations and substances; food supplements for nutritional or medical purposes.

Human cytomegalovirus CMV ; 1 diseases, including retinitis, colitis, and encephalitis, occur in 2540% of persons with AIDS 1, 2 ; and have been associated with decreased survival after diagnosis 35 ; . Considerable advances have been made in the treatment of AIDS patients with CMV disease and currently three drugs, ganciclovir, foscarnet, and cidofovir, have and trileptal. Users Don't Feel Well: Tobacco use makes people feel tired and run down. Exercise becomes difficult, if not impossible. Tobacco is Dangerous: Tobacco-related problems don't usually show up right away. But over time, many users develop serious health problems, because olanzapine litigation. Both intramuscular olanzapine and intramuscular haloperidol reduced agitation significantly more than intramuscular placebo 2 hours and 24 hours after the first injection. Intramuscular olanzapine reduced agitation significantly more than intramuscular haloperidol 15, 30 and 45 minutes after the first injection. No patients treated with intramuscular olanzapine experienced acute dystonia compared with 7% of those treated with intramuscular haloperidol. No significant QTc interval changes were observed in any patient and oxytetracycline. Order olanzapine

Most antipsychotics can cause weight gain, although the greatest mean weight gain has been associated with clozapine and olanzapine6. Of the atypical antipsychotics, amisulpride and aripiprazole are considered the lowest risk of causing weight gain2, 7. BMI should be monitored monthly for the first six months or at every visit on an outpatient basis1, 3. Patients should be encouraged to maintain a BMI between 18.5-25kg m2. Antipsychotic treatment should be reviewed if BMI 30kg m2 or if there is 5% weight gain over baseline8. Prevention of weight gain should be the primary objective by encouraging behavioural modification of diet and physical activity. First, followed by some of the common proprietary trade ; names. Drugs shown with underlining are not available under the Pharmaceutical Benefits Schemes [PBS] in Australia, i.e., they are not available at a subsidised price ; . Antipsychotics Amisulpride Solian ; Chlorpromazine Largactil ; Escitalopram Lexapro ; Fluphenazine Modecate ; Haloperidol Haldol, Serenace ; Moclobemide Auroix ; Olanzapine Zyprexa ; Promazine Promazine ; Quetiapine Seroquel ; Risperidone Risperdal ; Sulpiride Dolmatil, Sulparex, Sulpitil ; Trifluoperazine Stelazine ; Zuclopenthixol Clopixol ; Antidepressants Amitriptyline Endep ; Citalopram Cipramil, also Celapram, Ciazil, Talam, Talohexal ; Dothiepin Prothiaden, also Dothep ; Doxepin Sinequan, also Deptran ; Fluoxetine Prozac, also Lovan, Auscap, Fluohexal, Fluoxebell, Zactin ; Fluvoxamine Faverin, also Movax, Luvox, Voxam ; Imipramine Tofranil, also Tolerade ; Mirtazipine Avanza, Axit, Mirtazon, Remeron ; Nortriptyline Allegron ; Paroxetine Aropax, Paxtine, Oxetine ; Reboxetine Edronax ; Sertraline Zoloft, Xydep, Eleva, Concorz ; Venlafaxine Efexor ; Mood stabilisers Lithium carbonate Lithicarb, Quilonum ; Anxiety-relieving drugs Alprazolam Xanax, also Alprax, Kalma, Zamahexal ; Buspirone Buspar ; Diazepam Valium also Antenex, Valpam, Ducene and paroxetine. The international consensus group on bipolar i treatment guidelines recommended the following treatment strategies for patients who do not respond to first-line pharmacotherapy with lithium, lamotrigine, olanzapine, or olanzapine fluoxetine: for patients with a recent history of rapid cycling, add lithium, lamotrigine, olanzapine, or valproate.

Placebo-controlled comparison of efficacy and safety. J Psychiatry 159: 11461154 Sajatovic M 2002 ; Treatment of bipolar disorder in older adults. Int J Geriatr Psychiatry 17: 865873 Salloum I M, Thase M E 2000 ; Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2: 269280 Samren E B, van Duijn C M, Christiaens G C, Hofman A, Lindhout D 1999 ; Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46: 739746 Sato T, Bottlender R, Kleindienst N, Moller H J 2002 ; Syndromes and phenomenological subtypes underlying acute mania: a factor analytic study of 576 manic patients. J Psychiatry 159: 968974 Scott J 1996 ; Cognitive therapy of affective disorders: a review. J Affect Disord 37: 111 Scott J, Pope M 2002 ; Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 63: 384390 Scott J, Tacchi M J 2002 ; A feasibility study of the concordance therapy for individuals who are non-adherent with lithium. Bipolar Disord 4: 386392 Scott J, Stanton B, Garland A, Ferrier I N 2000 ; Cognitive vulnerability in patients with bipolar disorder. Psychol Med 30: 467472 Scott J, Garland A, Moorhead S 2001 ; A pilot study of cognitive therapy in bipolar disorders. Psychol Med 31: 459467 Shekelle P G, Woolf S H, Eccles M, Grimshaw J 1999 ; Clinical Guidelines: developing guidelines. BMJ 318: 593596 Smith L F, Whitfield M J 1995 ; Women's knowledge of taking oral contraceptive pills correctly and of emergency contraception: effect of providing information leaflets in general practice. Br J Gen Pract 45: 409414 Sproule B A, Hardy B G, Shulman K I 2000 ; Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 16: 165177 Storosum J G, Elferink A J, van Zwieten B J, van den Brink W, Gersons B P, van Strik R, Broekmans A W 2001 ; Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 11: 173180 Strakowski S M, McElroy S L, Keck P E Jr, West S A 1994 ; The Cooccurrence of mania with medical and other psychiatric disorders. Int J Psychiatry Med 24: 305328 Strakowski S M, DelBello M P, Fleck D E, Arndt S 2000 ; The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 48: 477485 Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush A J 1999 ; Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatmentresistant illness and a history of mania. J Psychiatry 156: 11641169 Suppes T, Dennehy E B, Swann A C, Bowden C L, Calabrese J R, Hirschfeld R M, Keck P E Jr, Sachs G S, Crismon M L, Toprac M G, Shon S P 2002 ; Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder. J Clin Psychiatry 63: 288299 Swann A C, Bowden C L, Calabrese J R, Dilsaver S C, Morris D D 2002 ; Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 26: 530536 Swartz H A, Frank E 2001 ; Psychotherapy for bipolar depression: a phase-specific treatment strategy? Bipolar Disord 3: 1122 ten Have M, Vollebergh W, Bijl R, Nolen W A 2002 ; Bipolar disorder in the general population in the Netherlands prevalence, consequences and care utilisation ; : results from the Netherlands mental health survey and incidence study NEMESIS ; . J Affect Disord 68: 203213 Terp I M, Mortensen P B 1998 ; Post-partum psychoses. Clinical diagnoses and relative risk of admission after parturition. Br J Psychiatry 172: 521526 Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, Walther A, Greil W 1996 ; Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 29: 103107 Tohen M, Sanger T M, McElroy S L, Tollefson G D, Chengappa K N, Daniel D G, Petty F, Centorrino F, Wang R, Grundy S L, Greaney M G, Jacobs T G, David S R, Toma V 1999 ; Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. J Psychiatry 156: 702709 Tohen M, Jacobs T G, Grundy S L, McElroy S L, Banov M C, Janicak P G, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson G D, Breier A 2000 ; Efficacy of olanzapine in acute bipolar and prandin. Recently, new-onset diabetes, ketoacidosis and some cases of pancreatitis have also been linked to olanzapine treatment. I myself have had to stop all psyhcedelics besides pot ; becuase of the consequences that will happen if i touch another drug and repaglinide and olanzapine, for example, olanzapine weight gain. Olanzapine has been studied in over 2500 schizophrenic patients worldwide Tran et al., 1997 ; . Safety evaluation in this significant database showed that olanzapine is generally well tolerated. It has been shown to be effective for the treatment of mainly negative and positive symptoms of schizophrenia and to have a mild side-effect profile. Its efficacy extends to patients who have prominent negative symptoms and whose disease process or age put them at increased risk for the serious side-effects of the conventional antipsychotic drugs, such as extrapyramidal symptoms and tardive dyskinesia. Olanzapine represents an important addition to the range of antipsychotic drugs currently available to the clinical psychiatrists. In treating negative and affective symptoms of schizophrenia but are equal in terms of positive symptom control. Risperidone may be more effective than conventional agents in treating positive and negative symptoms of schizophrenia. Quetiapine may be no more effective than conventional antipsychotic agents for any of the positive symptoms of schizophrenia. At present, it is unclear whether ziprasidone is more effective than conventional agents in treating negative symptoms. The efficacy of ziprasidone in treating positive symptoms appears to be comparable to haloperidol 15 mg day. Early data have yet to clearly show superiority of ziprasidone over conventional agents when treating negative symptoms. Perhaps the greatest difference between conventional and atypical agents as a group is the decreased likelihood of atypical agents to cause EPS. Compared to atypical agents, conventional agents cause 30% more EPS. With the exception of risperidone, the atypical agents also have less effect on prolactin. In the other categories of adverse events, data are mixed, effect sizes are quite small, and no clear differences have been identified. Although it is a widely held belief that atypical agents as a class are superior to conventional agents in treating negative symptoms of schizophrenia, there is still some controversy in this area and many issues should be considered. First, conventional agents also are superior to placebo in treating negative symptoms. Secondly, although large meta-analyses suggest that at recommended doses, risperidone and olanzapine are superior to haloperidol in providing improvement in negative symptoms, many of these comparative studies have been criticized for using the high-potency antipsychotic drug haloperidol in doses of 1020 mg day. These doses of haloperidol generally exceed current dosing recommendations and may result in drug-induced deficit or negative symptoms. Furthermore, the demonstrated superiority of atypical agents, although of statistical significance, is not striking in its magnitude. Studies comparing atypical agents to medium-potency conventional agents e.g., perphenazine ; have not been performed and pravastatin.